



**23 February 2016**

**AIM: RENE**

**ReNeuron Group plc**

**ReNeuron relocates to South Wales**

**Guildford, UK, 23 February 2016:** ReNeuron Group plc (the “Company”) (AIM: RENE), a leading UK-based stem cell therapy development company, is pleased to announce that, from 29 February 2016, its headquarters, research laboratories and manufacturing facilities will be located at a new purpose-built building on the Pencoed Business Park, just off the M4 motorway at Pencoed, South Wales.

From 29 February 2016, the address of the Company’s registered office will be:

Therapia Building  
Pencoed Business Park  
Pencoed, Bridgend  
CF35 5HY

The fit-out of the office accommodation and laboratories at the site is complete. Work is continuing, as planned, on the fit-out and eventual validation and licensing of the manufacturing areas of the facility.

**Olav Hellebø, Chief Executive Officer of ReNeuron, said:**

“We are delighted to be moving ReNeuron’s existing operations to our new facility at Pencoed, South Wales. When fully complete and licensed, we believe the building will house one of the world’s most advanced commercial cell therapy manufacturing facilities and we look forward to continuing to work with the Welsh Government to bring this important project to fruition.”

**Enquiries:**

**ReNeuron** +44 (0)20 3819 8400  
Olav Hellebø , Chief Executive Officer  
Michael Hunt, Chief Financial Officer

**Buchanan** +44 (0) 20 7466 5000  
Mark Court, Sophie Cowles, Stephanie Watson

**Cenkos Securities** +44 (0) 20 7397 8900  
Stephen Keys, Dr Christopher Golden (NOMAD and  
Broker)

Russell Kerr (Sales)

### **About ReNeuron**

ReNeuron is a leading, clinical-stage cell therapy development company. Based in the UK, its primary objective is the development of novel cell-based therapies targeting areas of significant unmet or poorly met medical need.

ReNeuron has used its unique stem cell technologies to develop cell-based therapies for significant disease conditions where the cells can be readily administered “off-the-shelf” to any eligible patient without the need for additional immunosuppressive drug treatments. The Company has therapeutic candidates in clinical development for motor disability as a result of stroke, for critical limb ischaemia and for the blindness-causing disease, retinitis pigmentosa.

ReNeuron is also advancing its proprietary exosome technology platform as a potential new nanomedicine targeting cancer and as a potential delivery system for gene therapy treatments.

ReNeuron’s shares are traded on the London AIM market under the symbol RENE.L. Further information on ReNeuron and its products can be found at [www.reneuron.com](http://www.reneuron.com).

*This announcement contains forward-looking statements with respect to the financial condition, results of operations and business achievements/performance of ReNeuron and certain of the plans and objectives of management of ReNeuron with respect thereto. These statements may generally, but not always, be identified by the use of words such as "should", "expects", "estimates", "believes" or similar expressions. This announcement also contains forward-looking statements attributed to certain third parties relating to their estimates regarding the growth of markets and demand for products. By their nature, forward-looking statements involve risk and uncertainty because they reflect ReNeuron's current expectations and assumptions as to future events and circumstances that may not prove accurate. A number of factors could cause ReNeuron's actual financial condition, results of operations and business achievements/performance to differ materially from the estimates made or implied in such forward-looking statements and, accordingly, reliance should not be placed on such statements.*